SRR1311575
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.437
- MYOGENESIS+0.345
- APICAL_SURFACE+0.334
- SPERMATOGENESIS+0.331
- PANCREAS_BETA_CELLS+0.329
- ESTROGEN_RESPONSE_LATE+0.244
- HEDGEHOG_SIGNALING+0.244
- ESTROGEN_RESPONSE_EARLY+0.209
- APICAL_JUNCTION+0.183
- XENOBIOTIC_METABOLISM+0.178
Top 10 suppressed
- MYC_TARGETS_V1-0.633
- PROTEIN_SECRETION-0.547
- UNFOLDED_PROTEIN_RESPONSE-0.518
- E2F_TARGETS-0.508
- G2M_CHECKPOINT-0.481
- MTORC1_SIGNALING-0.460
- MYC_TARGETS_V2-0.453
- DNA_REPAIR-0.422
- TGF_BETA_SIGNALING-0.354
- ANDROGEN_RESPONSE-0.327
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1499193 | GTEX | — | 0.964 |
| 2 | SRR1314958 | GTEX | — | 0.955 |
| 3 | SRR1337864 | GTEX | — | 0.953 |
| 4 | SRR1331751 | GTEX | — | 0.947 |
| 5 | SRR1396640 | GTEX | — | 0.943 |
| 6 | SRR1315761 | GTEX | — | 0.942 |
| 7 | SRR1330675 | GTEX | — | 0.940 |
| 8 | SRR1316815 | GTEX | — | 0.936 |
| 9 | SRR1418127 | GTEX | — | 0.934 |
| 10 | SRR1075898 | GTEX | — | 0.933 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.437 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.345 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.334 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.331 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.329 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.244 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.244 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.209 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.183 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.178 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.174 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.158 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.094 | Inavolisib | — uncovered |
| COAGULATION | 0.082 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.074 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.033 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.015 | Remibrutinib | — uncovered |